NO20043063L - Hoyren, oral fludara-formulering med hurtig frigjoring av virkestoffet - Google Patents

Hoyren, oral fludara-formulering med hurtig frigjoring av virkestoffet

Info

Publication number
NO20043063L
NO20043063L NO20043063A NO20043063A NO20043063L NO 20043063 L NO20043063 L NO 20043063L NO 20043063 A NO20043063 A NO 20043063A NO 20043063 A NO20043063 A NO 20043063A NO 20043063 L NO20043063 L NO 20043063L
Authority
NO
Norway
Prior art keywords
hoyren
fludara
oral
formulation
active substance
Prior art date
Application number
NO20043063A
Other languages
English (en)
Norwegian (no)
Inventor
Johannes-Wilhelm Tack
Ralph Lipp
Ulf Tilstam
Wolfgang Heil
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7711168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20043063(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20043063L publication Critical patent/NO20043063L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
NO20043063A 2001-12-20 2004-07-19 Hoyren, oral fludara-formulering med hurtig frigjoring av virkestoffet NO20043063L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10164510A DE10164510A1 (de) 2001-12-20 2001-12-20 Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
PCT/EP2002/013252 WO2003053418A1 (fr) 2001-12-20 2002-11-25 Formulation pour administration par voie orale, a liberation rapide du principe actif, contenant du fludara extra-pur

Publications (1)

Publication Number Publication Date
NO20043063L true NO20043063L (no) 2004-07-19

Family

ID=7711168

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043063A NO20043063L (no) 2001-12-20 2004-07-19 Hoyren, oral fludara-formulering med hurtig frigjoring av virkestoffet

Country Status (30)

Country Link
US (1) US7148207B2 (fr)
EP (1) EP1455760B1 (fr)
JP (2) JP2005519043A (fr)
KR (1) KR100884685B1 (fr)
CN (1) CN1306929C (fr)
AR (1) AR037965A1 (fr)
AT (1) ATE303797T1 (fr)
AU (1) AU2002349043B2 (fr)
BR (1) BR0215265A (fr)
CA (1) CA2471396A1 (fr)
DE (2) DE10164510A1 (fr)
DK (1) DK1455760T3 (fr)
EC (1) ECSP045185A (fr)
ES (1) ES2248624T3 (fr)
HK (1) HK1077741A1 (fr)
HR (1) HRP20040648B1 (fr)
IL (2) IL162555A0 (fr)
JO (1) JO2363B1 (fr)
MX (1) MXPA04006005A (fr)
NO (1) NO20043063L (fr)
NZ (1) NZ533701A (fr)
PE (1) PE20030639A1 (fr)
RS (1) RS50398B (fr)
RU (1) RU2318496C2 (fr)
SA (1) SA03240091B1 (fr)
TW (1) TWI255187B (fr)
UA (1) UA78741C2 (fr)
UY (1) UY27596A1 (fr)
WO (1) WO2003053418A1 (fr)
ZA (1) ZA200405735B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201190243A1 (ru) * 2009-05-19 2013-01-30 Гриндекс, Э Джоинт Сток Кампани Стабильная фармацевтическая композиция флударабина фосфата
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EP2428201A1 (fr) 2010-09-08 2012-03-14 Merck Serono S.A. Administration orale de nucléosides monophosphates
CN101947208B (zh) * 2010-10-09 2012-05-23 江苏奥赛康药业股份有限公司 一种供注射用的磷酸氟达拉滨组合物及其制备方法
CN102091046B (zh) * 2011-02-12 2012-07-18 海南锦瑞制药股份有限公司 一种磷酸氟达拉滨冻干粉针剂及其制备方法
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN111423458A (zh) * 2020-04-29 2020-07-17 东南大学 磷酸氟达拉滨杂质h对照品的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4188378A (en) 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4210745A (en) 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
DE3323621A1 (de) * 1982-07-08 1984-03-01 Yamasa Shoyu K.K., Choshi, Chiba Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier
US5110919A (en) 1989-12-04 1992-05-05 Ash Stevens, Inc. Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates
FR2701027B1 (fr) 1993-02-01 1997-07-18 Warner Lambert Co Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate.
DE19543052A1 (de) 1995-11-06 1997-05-07 Schering Ag Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
CA2210600A1 (fr) * 1996-07-17 1998-01-17 Takashi Houkan Inhibiteur des metastases tumorales ou de la recurrence
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
DE59807096D1 (de) * 1997-12-11 2003-03-06 Schering Ag Verfahren zur herstellung von fludarabin-phosphat-lithium-, natrium-, kalium-, calcium- und magnesium-salzen, reinigungsverfahren zur herstellung von fludarabin-phosphat und fludarabin-phosphat mit mindestens 99,5 %iger reinheit
JP4827296B2 (ja) 1998-06-11 2011-11-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー デラビルジン錠製剤
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
AU6646700A (en) 1999-08-20 2001-03-19 Scripps Research Institute, The Formation of heterocycles
DE60019741T2 (de) 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
CA2391950A1 (fr) * 1999-12-16 2001-06-21 Todd P. Foster Composition d'implant contenant de l'acetate de melengestrol et de l'acetate de trenbolone
US6399591B1 (en) 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets

Also Published As

Publication number Publication date
AU2002349043B2 (en) 2007-08-16
ECSP045185A (es) 2004-08-27
WO2003053418A1 (fr) 2003-07-03
DK1455760T3 (da) 2006-01-02
UY27596A1 (es) 2003-07-31
KR20040073501A (ko) 2004-08-19
TWI255187B (en) 2006-05-21
AU2002349043A1 (en) 2003-07-09
PL370792A1 (en) 2005-05-30
IL162555A0 (en) 2005-11-20
HRP20040648B1 (en) 2012-11-30
RS50398B (sr) 2009-12-31
HRP20040648A2 (en) 2004-10-31
RU2318496C2 (ru) 2008-03-10
CN1306929C (zh) 2007-03-28
AR037965A1 (es) 2004-12-22
RU2004122479A (ru) 2005-05-20
DE10164510A1 (de) 2003-07-10
RS53304A (en) 2006-10-27
ATE303797T1 (de) 2005-09-15
TW200305428A (en) 2003-11-01
JP2006137771A (ja) 2006-06-01
DE50204203D1 (de) 2005-10-13
ES2248624T3 (es) 2006-03-16
NZ533701A (en) 2006-03-31
HK1077741A1 (en) 2006-02-24
US20030176391A1 (en) 2003-09-18
US7148207B2 (en) 2006-12-12
IL162555A (en) 2008-03-20
JP2005519043A (ja) 2005-06-30
PE20030639A1 (es) 2003-08-28
BR0215265A (pt) 2004-12-07
KR100884685B1 (ko) 2009-02-18
CA2471396A1 (fr) 2003-07-03
SA03240091B1 (ar) 2006-11-25
MXPA04006005A (es) 2004-09-27
JO2363B1 (en) 2006-12-12
ZA200405735B (en) 2006-01-25
EP1455760B1 (fr) 2005-09-07
CN1617713A (zh) 2005-05-18
UA78741C2 (en) 2007-04-25
EP1455760A1 (fr) 2004-09-15

Similar Documents

Publication Publication Date Title
DK1145711T3 (da) Hurtig smeltende oral dosisformulering
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
PT1297825E (pt) Formas solidas de dosagem oral de simeticone
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20033384L (no) Farmasoytisk formulering
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
ATE353627T1 (de) Stabilisierte orale suspensionsformulierung
DE50204037D1 (de) Substituierte 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivate als arzneimittel gegen schmerz
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
ID30393A (id) Senyawa tienopirimidina, pembuatan dan penggunaannya
NO20033785D0 (no) Farmasöytisk formulering
NO20035627D0 (no) Farmasöytisk formulering
IL175303A0 (en) Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
NO20020793D0 (no) Virkestoffkombinasjon med clonidin
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
IS7582A (is) Hraðlosandi lyfjablanda
ATE334588T1 (de) Agrarchemikalienformulierung
NO20043063L (no) Hoyren, oral fludara-formulering med hurtig frigjoring av virkestoffet
FI20012143A0 (fi) Itiötön Bacillus subtilis, sen valmistus ja käyttö
IS2526B (is) Bensoxasepínafleiður og notkun þeirra sem AMPA viðtakahvatar
SI1532141T1 (sl) 2-pirolidin-2-il-(1,3,4)-oksadiazolni derivati in njihova uporaba kot antidepresivi
PT1373249E (pt) Derivados de imidazolidina, sua preparacao e sua utilizacao como agente anti-inflamatorio
FR2821754B1 (fr) Descenceur autobloquant
FR2834289B1 (fr) Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
NO20005856D0 (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application